BRUNO GUEDES BALDI
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina
22 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 22
- Clinical, demographic and functional evaluation of patients with hypersensitivity pneumonitis and their comparison based on current diagnostic criteria(2023) BRIDI, Guilherme Das Posses; SILVA, Bianca Freire Da; CUNHA, Marieta Cabral Amaral Da; QUEIROZ, Douglas Silva; ALVES- JR., Jose Leonidas; SALGE, Joao Marcos; CARVALHO, Celso R. F. De; KAIRALLA, Ronaldo Adib; SOUZA, Rogerio De; BALDI, Bruno Guedes
- Diagnosis and treatment of interstitial lung disease related to systemic autoimmune myopathies: a narrative review(2023) SOUZA, F. H. C. de; ARAUJO, D. B. de; HOFF, L. S.; BALDI, B. G.; FARIA, M. S. M. S.; ROCHA JUNIOR, L. F. da; SILVA, L. R. S. Da; PINTO, Behrens; BEZERRA, M. C.; MIOSSI, R.; CORDEIRO, R. A.; SHINJO, S. K.Systemic autoimmune myopathies (SAMs) are rare diseases that lead to muscle inflammation and may be associated with a variety of systemic manifestations. Although there is great heterogeneity in the spectrum of extra-muscular involvement in SAMs, interstitial lung disease (ILD) is the most frequent lung manifestation. SAM-related ILD (SAM-ILD) presents significant variations according to geographic location and temporal trends and is associated with increased morbidity and mortality. Several myositis autoantibodies have been discovered over the last decades, including antibodies targeting aminoacyl-tRNA synthetase enzymes, which are associated with a variable risk of developing ILD and a myriad of other clinical features. In this review, the most relevant topics regarding clinical manifestations, risk factors, diagnostic tests, autoantibodies, treatment, and prognosis of SAM-ILD are highlighted. We searched PubMed for relevant articles published in English, Portuguese, or Spanish from January 2002 to September 2022. The most common SAM-ILD patterns are nonspecific interstitial pneumonia and organizing pneumonia. The combination of clinical, functional, laboratory, and tomographic features is usually sufficient for diagnostic confirmation, without the need for additional invasive methods. Glucocorticoids remain the first-line treatment for SAM-ILD, although other traditional immunosuppressants, such as azathioprine, mycophenolate, and cyclophosphamide have demonstrated some efficacy and, therefore, have an important role as steroid-sparing agents.
- Metabolomic spittle analysis of post COVID-19 patients(2022) MACHADO, L.; PRUDENTE, R.; FRANCO, E.; GATTO, M.; MOTA, G.; PAGAN, L.; BRIZOLA, L.; SANTOS, M. Dos; CUNHA, T.; SABINO-SILVA, R.; FILHO, L.; MARTINS, M.; SANTOS, P.; MAIA, L.; ALBUQUERQUE, A.; MACHADO, E.; BALDI, B.; TANNI, S.
- Tomographic pleuropulmonary manifestations in rheumatoid arthritis: a pictorial essay(2023) BRIDI, Guilherme das Posses; SAWAMURA, Marcio Valente Yamada; WANDERLEY, Mark; SOUZA, Luciana Volpon Soares; KAIRALLA, Ronaldo Adib; KAWANO-DOURADO, Leticia; BALDI, Bruno GuedesRheumatoid arthritis ( RA) is an autoimmune inflammatory and heterogeneous disease that affects several systems, especially the joints. Among the extra- articular manifestations of RA, pleuropulmonary involvement occurs frequently, with different presentations, potentially in all anatomic thoracic compartments, and may determine high morbidity and mortality. The most common pleuropulmonary manifestations in patients with RA include interstitial lung disease (ILD), pleural disease, pulmonary arterial hypertension, rheumatoid lung nodules, airway disease (bronchiectasis and bronchiolitis), and lymphadenopathy. Pulmonary hypertension and ILD are the manifestations with the greatest negative impact in prognosis. HRCT of the chest is essential in the evaluation of patients with RA with respiratory symptoms, especially those with higher risk factors for ILD, such as male gender, smoking, older age, high levels of rheumatoid factor, or positive anti-cyclic citrullinated peptide antibody results. Additionally, other etiologies that may determine tomographic pleuropulmonary manifestations in patients with RA are infections, neoplasms, and drug-induced lung disease. In these scenarios, clinical presentation is heterogeneous, varying from being asymptomatic to having progressive respiratory failure. Knowledge on the potential etiologies causing tomographic pleuropulmonary manifestations in patients with RA coupled with proper clinical reasoning is crucial to diagnose and treat these patients.
- COVID-19 and pulmonary alveolar proteinosis: an unusual combination(2023) COLARES, Philippe de Figueiredo Braga; SILVA, Natalia Fernandes da; KAIRALLA, Ronaldo Adib; BALDI, Bruno Guedes
- Brazilian pulmonology guidelines on Delphi panel for post-coronavirus disease 2019(2023) TANNI, Suzana Erico; BALDI, Bruno Guedes; GODOY, Irma; BACHA, Helio Arthur; BARBOSA, Alexandre Naime; BERNARDO, Wanderley Marques
- Long-term respiratory follow-up of ICU hospitalized COVID-19 patients: Prospective cohort study(2023) CARVALHO, Carlos Roberto Ribeiro; LAMAS, Celina Almeida; CHATE, Rodrigo Caruso; SALGE, Joao Marcos; SAWAMURA, Marcio Valente Yamada; ALBUQUERQUE, Andre L. P. de; JR, Carlos Toufen; LIMA, Daniel Mario; GARCIA, Michelle Louvaes; SCUDELLER, Paula Gobi; NOMURA, Cesar Higa; GUTIERREZ, Marco Antonio; BALDI, Bruno GuedesBackgroundCoronavirus disease (COVID-19) survivors exhibit multisystemic alterations after hospitalization. Little is known about long-term imaging and pulmonary function of hospitalized patients intensive care unit (ICU) who survive COVID-19. We aimed to investigate long-term consequences of COVID-19 on the respiratory system of patients discharged from hospital ICU and identify risk factors associated with chest computed tomography (CT) lesion severity. MethodsA prospective cohort study of COVID-19 patients admitted to a tertiary hospital ICU in Brazil (March-August/2020), and followed-up six-twelve months after hospital admission. Initial assessment included: modified Medical Research Council dyspnea scale, SpO(2) evaluation, forced vital capacity, and chest X-Ray. Patients with alterations in at least one of these examinations were eligible for CT and pulmonary function tests (PFTs) approximately 16 months after hospital admission. Primary outcome: CT lesion severity (fibrotic-like or non-fibrotic-like). Baseline clinical variables were used to build a machine learning model (ML) to predict the severity of CT lesion. ResultsIn total, 326 patients (72%) were eligible for CT and PFTs. COVID-19 CT lesions were identified in 81.8% of patients, and half of them showed mild restrictive lung impairment and impaired lung diffusion capacity. Patients with COVID-19 CT findings were stratified into two categories of lesion severity: non-fibrotic-like (50.8%-ground-glass opacities/reticulations) and fibrotic-like (49.2%-traction bronchiectasis/architectural distortion). No association between CT feature severity and altered lung diffusion or functional restrictive/obstructive patterns was found. The ML detected that male sex, ICU and invasive mechanic ventilation (IMV) period, tracheostomy and vasoactive drug need during hospitalization were predictors of CT lesion severity(sensitivity,0.78 +/- 0.02;specificity,0.79 +/- 0.01;F1-score,0.78 +/- 0.02;positive predictive rate,0.78 +/- 0.02; accuracy,0.78 +/- 0.02; and area under the curve,0.83 +/- 0.01). ConclusionICU hospitalization due to COVID-19 led to respiratory system alterations six-twelve months after hospital admission. Male sex and critical disease acute phase, characterized by a longer ICU and IMV period, and need for tracheostomy and vasoactive drugs, were risk factors for severe CT lesions six-twelve months after hospital admission.
- Repercussions of the COVID-19 pandemic for science and for the management of the Jornal Brasileiro de Pneumologia(2022) BALDI, Bruno Guedes; PIZZICHIN, Marcia Margaret Menezes
- Late Breaking Abstract - Artificial intelligence-based dec---sion support for HRCT stratification in fibrotic lung disease; an international study of 116 observers from 37 countries.(2023) CALANDRIELLO, Lucio; MACKINTOSH, John; FELDER, Federico; AGRAWAL, Aditya; ALAMOUDI, Omer; ALBERTI, Laura; AQUARO, Giuseppe; ARENAS-JIMENEZ, Juan; AU-YONG, Iain; AVDEEV, Sergey; BALBI, Maurizio; BALDI, Bruno; BAN, Andrea Yu-Lin; BELACONI, Ionela-Nicoleta; BENDSTRUP, Elisabeth; BENNETT, David; BLUM, Hans-Christian; BARIGA, Nicola Boscolo; BOZOVIC, Gracijela; BROQI, Marsel; BRUZZI, John; BUENDIA-ROLDAN, Ivette; CALARAS, Diana; CAMPAINHA, Sergio; CARBONE, Roberto G.; CARVALHO, Andre; CERESER, Lorenzo; CHAI, Gin Tsen; CHAUDHARY, Sachin; CHAUDHURI, Nazia; CHEONG, Patrick Alain Chui Wan; COOPER, Wendy; CUTAIA, Giuseppe; D'ABRONZO, Rosa; KRUIF, Martijn D. De; DELGADO-GARCIA, Diemen; DHOORIA, Sahajal; DIAZ-CASTANON, Jesus J.; EIGER, Glenn; ELLIS, Samantha; ESTRADA-Y-MARTIN, Rosa; FANG, Yingying
- Current Understanding of Post-COVID Pulmonary Fibrosis: Where Are We?(2023) BRIDI, Guilherme das Posses; TANNI, Suzana Erico; BALDI, Bruno Guedes
- «
- 1 (current)
- 2
- 3
- »